Thank you, Michael, and thank you all for joining the Hercules Capital Q3 2024 earnings call. Our strong operating results for the third quarter and year-to-date through Q3 2024 reflect our leadership position in the venture and growth stage lending market, as well as the benefits of operating at scale with an institutional lending platform and a seasoned best-in-class investment team. In Q3 2024, the Company delivered record total investment income of $125.2 million an increase of 7.3% year-over-year. Year-to-date, the Company has delivered record total investment income of $371.8 million an increase of 10% year-over-year as well as record NII of $244.7 million or $1.52 per share, an increase of 12.2% year-over-year. As of the end of Q3, Hercules Capital is managing approximately $4.6 billion of assets, an increase of 10.9% from where we were a year ago. Hercules has delivered record year-to-date ending Q3 2024 total gross fundings of $1.34 billion despite intentionally slowing down new originations in Q3. Q3 is typically a slower quarter in terms of equity capital investments and overall activity across the venture ecosystem, and this year was no different. The venture and growth stage markets slowed considerably in Q3, particularly with respect to venture capital investment activity and venture capital M&A exit activity. This slowdown combined with many quality scaled borrowers putting off debt decisions until after the upcoming presidential election and waiting for the recent Fed interest rate action resulted in a new business environment that our investment teams did not believe was favorable for disciplined and prudent capital deployment, particularly early in the quarter. Every decision that we make as a Company is centered around what we believe is in the best long term interest of our shareholders, stakeholders and borrowers, and this time was no different. As we continue to manage our balance sheet, leverage and business conservatively, we remain very well-positioned to deliver another year of outstanding results and record operating performance for our shareholders. Through the remainder of the year, we continue to expect higher than normal market and macro volatility, given the upcoming presidential election and the ongoing challenges taking place in the global geopolitical environment. After the recent Fed interest rate action, we have started to see an uptick in the number of quality later-stage companies looking to secure growth stage debt financing, and we have also seen a recent pickup in the venture capital investment activity quarter-to-date. Our current pending commitments of approximately $630 million reflect the change in environment that we have seen post quarter-end. As a result, we remain optimistic about our funding activity for the remainder of Q4, and we expect to deliver another record year of new gross fundings for fiscal year 2024. Through year-end, we intend to continue to manage our business and balance sheet defensively, while maintaining maximum flexibility to take advantage of market opportunities. This includes continuing to enhance our liquidity position, maintaining low leverage, further tightening our credit screens on new underwritings and maintaining our higher than normal first lien exposure, which was at 89.5% in Q3 compared to 90.1% in Q2. We believe that positioning ourselves to be able to take advantage of the market when it is more attractive to do so will be a key differentiator of our business going forward. Let me now recap some of the key highlights of our performance for Q3. In Q3, we originated total gross debt and equity commitments of over $430 million and gross fundings of $272 million. Year-to-date, we have committed in excess of $2.07 billion of capital and we have delivered record funding performance over the same period. As a result and as previously mentioned, in Q3 2024, we generated record total investment income of $125.2 million up over 7% year-over-year and net investment income of $83.2 million up over 8% year-over-year or $0.51 per share, providing 128% coverage of our base distribution of $0.40 per share. We were able to achieve 128% coverage of our base distribution despite ending the quarter with very conservative GAAP leverage of 94.6%. This is our sixth consecutive quarter of over $100 million of quarterly core income, which excludes the benefit of prepayment fees or fee accelerations from early repayments. This puts us in a very solid position to be able to continue to comfortably cover our quarterly base distribution despite the declining rate environment. We also generated return on equity in Q3 of 18. 9%. Our portfolio generated a GAAP effective yield of 14.4% in Q3 and a core yield of 13.3%. Our balance sheet with conservative leverage and low cost of leverage remains very well-positioned to support our continued growth objectives and provides us with the ability to go lower on yield and larger in size for higher quality assets when warranted. This again serves as a key differentiator of our business. The focus of our origination efforts in Q3 was on maintaining a disciplined approach to capital deployment. Our deal screening activity during the quarter was high, but we simply did not see enough quality deals to warrant aggressive deployment of capital. As an internally managed BDC that prioritizes credit, we have the luxury of not chasing the market when we do not believe that the credit quality on new originations supports it. Our Q3 originations activity was driven by both our technology and life sciences teams once again. In Q3, approximately 61% of our fundings were to technology companies, while approximately 56% of our new commitments were to life sciences companies. We funded debt capital to 21 different companies in Q3, of which four were new borrower relationships. This is reflective of our approach during the quarter to prioritize capital deployment within the portfolio, where we know the credit quality and performance history of the underlying borrowers. We also increased our capital commitments to several portfolio companies during the quarter, which speaks to our ability to scale alongside our borrowers as they continue to grow their businesses. Our available unfunded commitments increased slightly to approximately $489 million from $479.5 million in Q2. The quality of the growth stage companies looking for debt financing has improved following the recent Fed rate cut and based on active conversations that our teams are having throughout the ecosystem, we expect this to improve further post the U.S. presidential election. Since the close of Q3 and as of October 25, 2024, our deal team has closed $17 million of new commitments and funded $15.2 million. We have pending commitments of an additional $630 million in signed non-binding term sheets, and we expect this number to continue to grow as we progress in Q4. Similar to what we saw in Q3, our expectation is that Q4 funding activity will be back-end weighted. Our focus for Q4 will remain on asset quality and prudent underwriting. In Q3, we had four total M&A events in our portfolio, which included three life sciences portfolio companies signing definitive agreements to be acquired and one technology portfolio company being acquired. Year-to-date, we’ve had 10 portfolio companies announce or complete an M&A event. Last year at this time, we had 13 portfolio company M&A events. So, our exit activity remains healthy, but slower than last year. Early loan repayments decreased in Q3 to approximately $230 million which was within our guidance of $200 million to $300 million. Over 52% of our Q3 prepayments were attributable to M&A events or new equity capital events, which we view as a positive signal overall. For Q4 2024, we expect prepayments to be in the range of $150 million to $250 million although this could change as we progress in the quarter. Credit quality of the debt investment portfolio remains strong quarter-over-quarter. Our weighted average internal credit rating of 2.24 increased slightly from the 2.18 rating in Q2, and it remains at the lower-end of our normal historical range. Our Grade 1 and Grade 2 credits decreased slightly to 65.2% compared to 67.2% in Q2. Grade 3 credits increased slightly to 31.9% in Q3 versus 31% in Q2. Our Rated 4 credits increased to 2.3% from 0.9% in Q2, and our Rated 5 credits decreased to 0.6%. In Q3, the number of loans and companies on non-accrual remained the same. We had two debt investments on non-accrual with an investment cost and fair value of approximately $92.2 million $20.7 million respectively, or 2.6% and 0.6% as a percentage of the Company’s total investment portfolio at cost and value, respectively. Based on the most recent updates that we have, we expect to largely conclude our convoy workout efforts in Q4 as well as have a resolution to the [Coros] (ph) loan before the end of the year. With respect to our broader credit book and outlook, we generally remain pleased by what we are seeing on a portfolio level and our portfolio monitoring remains enhanced. Our focus on credit underwriting and a diversified asset base is going to continue to serve us well. During Q3 2024, Hercules had net realized losses of $0.6 million comprised of gross realized gains of $2.8 million primarily due to the gain on equity investments, offset by $3.4 million primarily driven due to losses on warrant and equity investments. Our net asset value per share in Q3 was $11.40 a very small decrease of 0.3% from Q2 2024. We ended Q3 with strong liquidity of $572.3 million. Our liquidity position includes our fourth SBIC license, which we received in July. Our fourth license provides access to $175 million of additional growth capital and will help us to maintain our overall blended cost of capital. Our balance sheet with excess liquidity, a low cost of debt relative to our peers and four investment grade corporate credit ratings continues to position us well and afford us the ability to compete aggressively on quality transactions. As discussed earlier, we saw a significant slowdown in the venture capital ecosystem during Q3 in terms of some of the key metrics that we monitor. Venture capital investment activity of $37.5 billion in Q3 was down 32% from Q2 levels. This was the slowest Q3 in the last four years in terms of venture capital equity investment activity. Year-to-date, venture capital investment activity was approximately $131.4 billion which is largely flat from the same period a year ago according to data gathered by Pitchbook-NVCA. We also saw M&A exit activity for U.S. venture capital backed companies pull back considerably in Q3 to $7.4 billion down from $18.5 billion in Q2. Year-to-date ended Q3 2024, fundraising activity was steady relative to last year at approximately $65.1 billion. Despite the slowdown in Q3, we believe that the ecosystem remains healthy and that the recent numbers reflect a reversion back to the historical norm, the uncertainty surrounding the upcoming U.S. presidential election and a lack of clarity around near-term Fed actions. Consistent with the aggregate data for the ecosystem during Q3, capital raising across our portfolio was down with 18 companies raising approximately $600 million in new capital, down from $1.7 billion raised in Q2 and $2.6 billion raised in Q1. Year-to-date ending Q3, we had 58 portfolio companies raise over $4.9 billion of new capital, which is nearly the same amount of equity capital that our portfolio companies raised last year through the same period. Given our strong operating performance in Q3, we exited the quarter with undistributed earnings spillover increasing to over $152 million or $0.94 per ending shares outstanding. For Q3, we announced our base distribution of $0.40 and a supplemental distribution of $0.08. This represents our 17th consecutive quarter of being able to provide our shareholders with a supplemental distribution on top of our regularly quarterly base distribution. In closing, our scale institutionalized lending platform and our ability to capitalize on a rapidly changing competitive and macro environment continues to drive our business forward and our operating performance to record levels. In Q3, Hercules delivered its sixth consecutive quarter of over $100 million of quarterly core income, which excludes the benefit of prepayment fees or fee accelerations from early repayments. Our success is attributable to the tremendous dedication, efforts and capabilities of our 100 plus full-time employees and the trust that our venture capital and private equity partners place with us every day. We are thankful to the many companies, management teams and investors that continue to make Hercules Capital their partner of choice. I will now turn the call over to, Seth.